THE TAPE

Immunome, Inc.

$17.61▼ −6.18%
Last close
Relative strength
18RS
of 99, against every stock▲ +4 on the month
Turning up
Unconfirmed
−20.3%
six months against Pharmaceutical Preparations
52-week range
−41.4%
from the high
$16.11$30.06
Setup
vcpplayed out
−30.4%
against the pivot at $25.30
Today
Nov 16 · confirmed
Growth FLATProof PENDING
Quarter to Sep 30
11/16 O 18.50 H 19.15 L 17.55 Vol 1.5M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS18
vs pivot−30.40%
Tightening1.34×
Dry-up1.80×
Up/down vol-0.10
From high41%
earnings in 0dplayed out2 of 9checks
Turning up
Support and resistance
Support below
None within the last 120 sessions
Resistance above
$18.67
+6.0% · tested 3× · last 18 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 5.0 weeks and fell 24% from its ceiling at its deepest. The pivot is $25.30, and the stock closed 30.4% below it. Its relative strength rating is 18.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
+2.4%
Three months against its industry
-26.2%
Six months against its industry
-20.3%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap
0
days
Earnings today
Nov 16, 2026
  1. Earningsconfirmedin 0d
    Quarterly earnings
    Nov 16, 2026
How it moves on earnings

On average 5.1% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
—
Operating margin
—
Net margin
—
Free cash flow
$-238.7M
-11.9% of market cap
Price to sales
—
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 9
Key takeaway
Cash flow is the weak point of the quarter.
Revenue
—
Gross margin
—
Net income
−$85.8M
Loss
Free cash flow
−$61.2M
Burning · 4q runway

What the numbers say

  • Weak: Net loss $86M, wider than $73M last quarter
  • Weak: Burning cash: operating cash flow -$61M, free cash flow -$61M, better than -$64M last quarter · 4 quarters of cash at this burn
  • Weak: Growth externally funded: capex $489K against operating cash flow -$61M; share count +29.1% in a year
  • Good: Net cash $213M · cash $213M
Revenue by quarter
Free cash flow
Net income
shares +29.1% in a year · net cash $212.8M

What is not obvious

  • Weak: Stock compensation $13M added back against negative operating cash flow
Final read
Growth: FLAT · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is operating profit: net loss $86M, wider than $73M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Tightening after a sharp runTape · 2026-11-13
range halved after a +17% thrust, at 18.70
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).
GappedTape · 2026-11-06
-8.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-05
3.6 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
GappedTape · 2026-11-03
+7.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Earnings date movedEvent · 2026-10-27
2026-11-04 -> 2026-11-16
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
GappedTape · 2026-10-21
+6.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-14
-8.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-07
-8.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should KnowZacks Investment Research · 13 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders
Bought on the open market
3
$204,260 total
Sold on the open market
21
$16,213,601 total

Bought: BIENAIME JEAN JACQUES. Sold: Higgins Jack, Barchas Isaac, Horn Kinney, Lechleider Robert, Rosett Max, BIENAIME JEAN JACQUES.

Not counted above: 15 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-09-11 Higgins Jack · Chief Scientific Officeroption exercise18,000$24,300
2026-09-11 Higgins Jack · Chief Scientific Officersell13,200$334,224
2026-09-11 Higgins Jack · Chief Scientific Officergift8,800
2026-08-12 Barchas Isaac · Directorsell11,048$301,058
2026-08-11 Barchas Isaac · Directorsell62,291$1,633,893
2026-08-10 Barchas Isaac · Directorsell10,125$263,959
2026-08-07 Barchas Isaac · Directorsell15,248$397,363
2026-08-06 Barchas Isaac · Directorsell20,840$543,090

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

2 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy3
Buy13
Hold1
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Immunome, Inc. (IMNM) — The Tape